Patanjali Foods

Patanjali’s daily technical setup shows a sharp, short-term rebound within a longer-term downtrend. As of November 6, 2026, the stock closed at ₹411.50, up +0.2% for the day but significantly higher over the past month (+13.4%) and ten days (+17.7%). This recent strength is supported by high-volume anomalies on October 28 (+6.2%, volume ratio 4.18) and November 5 (+7.0%, volume ratio 3.67), indicating active participation in the move upward. Daily indicators are bullish: price trades above the 20-day and 50-day EMAs and SMAs, with a Supertrend signal pointing bullish and ADX at 24.41 suggesting developing trend strength.

However, this daily bounce contrasts with the monthly structure, where the price remains below all major moving averages and the Supertrend is bearish, reflecting a -28.2% one-year return and a current drawdown of -38.3%. The stock is positioned near the upper end of its 20-day range (+92.6%) but only in the lower-middle of its 252-day range (+29.1%). Immediate resistance lies at ₹423.83 (3.0% above), while support is found at ₹406.35 (1.25% below). The setup suggests a counter-trend rally; confirmation of sustained reversal requires holding above key daily averages, while failure to break ₹423.83 may see pressure resume toward monthly support levels.

In the seven-day window ending November 4, 2026, Patanjali Foods Ltd faced significant regulatory scrutiny in Maharashtra. Between October 28 and 31, the state Food and Drug Administration (FDA) conducted inspections that led to the confiscation of 3,53,000 kg of goods valued at ₹9.01 crore and the suspension of 19 licenses due to hygiene violations and suspected adulteration. This action included 13 FIRs and 16 arrests, with specific seizures involving 2,279.7 litres of Patanjali ghee from a distributor in Chhatrapati Sambhajinagar, alongside oil and other food items in Mumbai, Amravati, and Satara.

On November 3, the company disclosed that FDA officials had collected samples of certain batches of its Cow Ghee for laboratory testing, imposing restrictions on the sale of the identified stock pending further action. Patanjali emphasized that no authenticated report has yet confirmed quality standard violations or adulteration, noting that the initial regulatory communication was received by a distributor rather than directly by the company. The firm stated it is cooperating with authorities and will make further disclosures to stock exchanges only if material developments or authenticated test results emerge.

On November 6, 2026, Patanjali Foods Limited filed a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlighting significant shifts in its revenue mix and growth trajectory. The company reported that e-commerce channels, including quick commerce, now account for nearly 35% of total channel revenue, underscoring a structural pivot toward digital distribution. Simultaneously, the institutional business segment recorded 50% year-on-year growth. These developments are framed by the company as part of a broader strategy to diversify revenue streams and strengthen its overall distribution ecosystem. This filing provides fresh visibility into the operational dynamics driving the listed entity's top-line composition.

Patanjali Foods Limited disclosed significant operational shifts and regulatory challenges in late October 2026. The company reported that e-commerce, including quick commerce, now accounts for nearly 35% of total channel revenue, while its institutional business grew 50% year-on-year, reflecting a strategic diversification of its distribution ecosystem.

Conversely, the company faced multiple regulatory actions regarding its Cow Ghee product. In Chhindwara (order dated October 16) and Burhanpur (order dated October 21), local food authorities prohibited the sale or ordered the recall of specific batches deemed unsafe or non-compliant with Food Safety and Standards regulations. Patanjali stated these incidents have no material financial impact beyond the value of the affected batches and indicated it would appeal the orders. Additionally, on November 3, the Maharashtra FDA initiated action against stock held by a super distributor; however, as of that date, no authenticated laboratory report confirmed adulteration or substandard quality.

On the governance front, the company’s 40th Annual General Meeting was held on September 29, 2026, where shareholders approved interim dividends totaling ₹5.00 per share (₹1.75 + ₹1.75 + ₹1.50) and re-appointed Acharya Balkrishna as a director. Shareholding data as of September 30, 2026, showed promoters holding 68.25% and the public holding 31.75%. Separately, Crisil ESG Ratings assigned an independent ESG score of 59 and a Core ESG score of 66 based on fiscal 2026 disclosures.

Patanjali Foods demonstrates a divergence between top-line momentum and bottom-line execution in the most recent reporting period. For Q4 FY2025-26, revenue from operations rose sequentially to ₹11,155.60 crore, continuing a strong YoY sales growth trajectory of 20% observed in the trailing twelve months (TTM). However, profitability contracted significantly: Net Profit fell to ₹523.98 crore from ₹593.44 crore in Q3, and Profit Before Tax dropped sharply to ₹235.65 crore from ₹364.23 crore. This decline occurred despite a sequential decrease in Other Expenses to ₹731.84 crore, suggesting margin compression or non-operating headwinds impacted the final result.

Financial health metrics present mixed signals. While the company reduced borrowings from ₹1,049 crore in Mar 2024 to ₹788 crore in Mar 2025, leverage surged to ₹2,789 crore by Mar 2026, coinciding with a rise in Equity Capital to ₹218 crore. Cash flow quality has deteriorated markedly; Cash from Operating Activity swung from positive ₹1,746 crore in Mar 2024 to negative ₹333 crore in Mar 2026, and the CFO/EBITDA ratio turned negative at -20.0%. Working capital efficiency also weakened, with the Cash Conversion Cycle extending to 76 days in Mar 2026 from 46 days in Mar 2024, driven largely by an increase in Inventory Days to 79 days. Institutional ownership shifted notably, with FIIs reducing their stake to 7.24% in Sep 2026, while DIIs increased theirs to 12.51%.

Patanjali Foods faces significant operational and regulatory headwinds following a crackdown by the Maharashtra Food and Drug Administration (FDA) between October 28 and 31. Authorities confiscated 3,53,000 kg of goods valued at ₹9.01 crore and suspended 19 licenses due to hygiene violations and suspected adulteration, resulting in 13 FIRs and 16 arrests. Specific seizures included 2,279.7 litres of Cow Ghee from a distributor in Chhatrapati Sambhajinagar. While the company states that no authenticated report has yet confirmed quality standard violations for all batches, it disclosed that food safety officials collected samples of certain Cow Ghee batches for testing, with sales restrictions pending further action. This regulatory scrutiny introduces uncertainty regarding product integrity and distribution continuity.

Market performance reflects this cautionary backdrop. The stock is down -25.5% year-to-date and -28.2% over the past year, trading at ₹411.5 as of November 6, 2026. Technical indicators show a mixed signal: while the daily Supertrend remains bullish, the monthly trend is bearish, and the stock is currently in a -38.3% drawdown from its peak. Immediate support exists near ₹400.77, but resistance looms just 3% higher at ₹423.83.